Aspergillosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, the industry analysis specialist, has released its new report, “Aspergillosis Therapeutics Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Aspergillosis Therapeutics market. The report identifies the key trends shaping and driving the global Aspergillosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Aspergillosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Aspergillosis Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Aspergillosis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Aspergillosis Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Aspergillosis Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Aspergillosis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Aspergillosis Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Aspergillosis Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Aspergillosis Therapeutics market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Aspergillosis Therapeutics - Introduction 7
2.1 Overview 7
2.2 Epidemiology 7
2.3 Etiology 7
2.4 Symptoms 7
2.5 Diagnosis 8
2.6 Pathophysiology 8
2.7 Treatment and Management Pattern 9
2.8 GlobalData Pipeline Report Guidance 10

3 Aspergillosis Therapeutics - Market Characterization 11
3.1 Overview 11
3.2 Aspergillosis Therapeutics Market Size (2006-2011) - Global 11
3.3 Aspergillosis Therapeutics Market Forecast (2011-2019) - Global 13
3.4 Aspergillosis Therapeutics Market Size (2006-2011) - The US 14
3.5 Aspergillosis Therapeutics Market Forecast (2011-2019) - The US 15
3.6 Aspergillosis Therapeutics Market Size (2006-2011) - France 16
3.7 Aspergillosis Therapeutics Market Forecast (2011-2019) - France 17
3.8 Aspergillosis Therapeutics Market Size (2006-2011) - Germany 18
3.9 Aspergillosis Therapeutics Market Forecast (2011-2019) - Germany 19
3.10 Aspergillosis Therapeutics Market Size (2006-2011) - Italy 20
3.11 Aspergillosis Therapeutics Market Forecast (2011-2019) - Italy 21
3.12 Aspergillosis Therapeutics Market Size (2006-2011) - Spain 22
3.13 Aspergillosis Therapeutics Market Forecast (2011-2019) - Spain 23
3.14 Aspergillosis Therapeutics Market Size (2006-2011) - The UK 24
3.15 Aspergillosis Therapeutics Market Forecast (2011-2019) - The UK 25
3.16 Aspergillosis Therapeutics Market Size (2006-2011) - Japan 26
3.17 Aspergillosis Therapeutics Market Forecast (2011-2019) - Japan 27
3.18 Drivers and Barriers for the Aspergillosis Therapeutics Market 28
3.18.1 Drivers for the Aspergillosis Therapeutics Market 28
3.18.2 Barriers for the Aspergillosis Therapeutics Market 28
3.19 Opportunity and Unmet Need 29
3.20 Key Takeaway 30

4 Aspergillosis Therapeutics Market - Competitive Assessment 31
4.1 Overview 31
4.2 Strategic Competitor Assessment 31
4.3 Product Profiles of the Major Marketed Products in the Aspergillosis Therapeutics Market - Heparin Class 32
4.3.1 Voriconazole (Vfend) 32
4.3.2 Posaconazole (Noxafil) 33
4.3.3 Itraconazole (Sporanox) 34
4.3.4 Caspofungin (Cancidas) 34
4.3.5 Amphotericin B (Amphocin) 35
4.4 Key Takeaway 35

5 Aspergillosis Therapeutics Market - Pipeline Assessment 36
5.1 Overview 36
5.1.1 Aspergillosis Therapeutics - Phase III Clinical Pipeline 36
5.1.2 Aspergillosis Therapeutics - Phase II Clinical Pipeline 36
5.1.3 Aspergillosis Therapeutics - Phase I Clinical Pipeline 36
5.1.4 Aspergillosis Therapeutics - Preclinical and Discovery Clinical Pipeline 37
5.2 Aspergillosis Therapeutics Market - Pipeline Assessment by Mechanism of Action 38
5.3 Aspergillosis Therapeutics Market - Technology Trends Analytical Framework 39
5.4 Aspergillosis Therapeutics Market - Pipeline Assessment by Clinical Phase of Development 40
5.5 Molecule Profile for Drugs under Clinical Development 41
5.5.1 Isavuconazole 41
5.5.2 SPK-843 41
5.6 Key Takeaway 42

6 Aspergillosis Therapeutics - Clinical Trials Mapping 43
6.1 Clinical Trials by Region/Country 43
6.2 Clinical Trials by Phase of Clinical Development 44
6.3 Clinical Trials by Trial Status 45
6.4 Prominent and Overall Sponsors 46
6.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials 48

7 Aspergillosis Therapeutics - Strategic Assessment 49
7.1 Key Events Impacting the Future Market 49
7.2 Future Market Competition Scenario 50

8 Aspergillosis Therapeutics - Future Players 51
8.1 Introduction 51
8.2 Company Profiles 52
8.2.1 Pfizer Inc. 52
8.2.2 Astellas Pharma Inc. 53
8.2.3 Basilea Pharmaceutica Ltd. (Basilea) 54

9 Aspergillosis Therapeutics - Acquisition Deals 55

10 Aspergillosis Therapeutics Market - Appendix 58
10.1 Market Definition 58
10.2 Abbreviations 58
10.3 Methodology 58
10.3.1 Coverage 59
10.3.2 Secondary Research 59
10.3.3 Forecasting 59
10.3.4 Primary Research 62
10.3.5 Expert Panel Validation 62
10.4 Contact Us 62
10.5 Disclaimer 62
10.6 Bibliography 63

List of Tables

Table 1: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2006-2011 12
Table 2: Aspergillosis Therapeutics Market, Global, Market Forecasts ($m), 2011-2019 13
Table 3: Aspergillosis Therapeutics Market, The US, Revenue ($m), 2006-2011 14
Table 4: Aspergillosis Therapeutics Market, The US, Market Forecasts ($m), 2011-2019 15
Table 5: Aspergillosis Therapeutics Market, France, Revenue ($m), 2006-2011 16
Table 6: Aspergillosis Therapeutics Market, France, Market Forecast ($m), 2011-2019 17
Table 7: Aspergillosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 18
Table 8: Aspergillosis Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 19
Table 9: Aspergillosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 20
Table 10: Aspergillosis Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 21
Table 11: Aspergillosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 22
Table 12: Aspergillosis Therapeutics Market, Spain, Market Forecast ($m), 2011-2019 23
Table 13: Aspergillosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 24
Table 14: Aspergillosis Therapeutics Market, The UK, Market Forecast ($m), 2011-2019 25
Table 15: Aspergillosis Market, Japan, Revenue ($m), 2006-2011 26
Table 16: Aspergillosis Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 27
Table 17: Aspergillosis Therapeutics Market - Phase III Clinical Pipeline, 2010 36
Table 18: Aspergillosis Therapeutics Market - Phase II Clinical Pipeline, 2010 36
Table 19: Aspergillosis Therapeutics Market - Phase I Clinical Pipeline, 2010 36
Table 20: Aspergillosis Therapeutics Market - Preclinical Pipeline, 2010 37
Table 21: Aspergillosis Market, Global, Clinical Trials by Country, 2010 43
Table 22: Aspergillosis Market, Global, Clinical Trials by Phase, 2010 44
Table 23: Aspergillosis Market, Global, Clinical Trials by Status of Development, 2010 45
Table 24: Aspergillosis Market, Global, Sponsors, 2010 47
Table 25: Aspergillosis Market, Global, Companies by Phase, 2010 48
Table 26: Aspergillosis Therapeutics, Global, Deals, 2011 55

List of Figures

Figure 1: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2006-2011 11
Figure 2: Aspergillosis Therapeutics Market, Global, Market Forecast ($m), 2011-2019 13
Figure 3: Aspergillosis Therapeutics Market, The US, Revenue ($m), 2006-2011 14
Figure 4: Aspergillosis Therapeutics Market, The US, Market Forecasts ($m), 2011-2019 15
Figure 5: Aspergillosis Therapeutics Market, France, Revenue ($m), 2006-2011 16
Figure 6: Aspergillosis Therapeutics Market, France, Market Forecast ($m), 2011-2019 17
Figure 7: Aspergillosis Therapeutics Market, Germany, Revenue ($m), 2006-2011 18
Figure 8: Aspergillosis Therapeutics Market, Germany, Market Forecast ($m), 2011-2019 19
Figure 9: Aspergillosis Therapeutics Market, Italy, Revenue ($m), 2006-2011 20
Figure 10: Aspergillosis Therapeutics Market, Italy, Market Forecast ($m), 2011-2019 21
Figure 11: Aspergillosis Therapeutics Market, Spain, Revenue ($m), 2006-2011 22
Figure 12: Aspergillosis Therapeutics Market, Spain, Market Forecast ($m), 2011-2019 23
Figure 13: Aspergillosis Therapeutics Market, The UK, Revenue ($m), 2006-2011 24
Figure 14: Aspergillosis Therapeutics Market, The UK, Market Forecast ($m), 2011-2019 25
Figure 15: Aspergillosis Therapeutics Market, Japan, Revenue ($m), 2006-2011 26
Figure 16: Aspergillosis Therapeutics Market, Japan, Market Forecast ($m), 2011-2019 27
Figure 17: Opportunity and Unmet Need in the Aspergillosis Therapeutics Market 29
Figure 18: Strategic Competitor Assessment of the Marketed Products for Aspergillosis, 2010 31
Figure 19: Aspergillosis Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2010 38
Figure 20: Technology Trends Analytic Framework of the Aspergillosis Pipeline, 2010 39
Figure 21:  Technology Trends Analytic Framework of the Aspergillosis Pipeline - Description, 2010 40
Figure 22: Aspergillosis Pipeline by Phase of Clinical Development, 2010 40
Figure 23: Aspergillosis Market, Global, Clinical Trials by Country, 2010 43
Figure 24: Aspergillosis Market, Global, Clinical Trials by Phase, 2010 44
Figure 25: Aspergillosis Market, Global, Clinical Trials by Stage of Development, 2010 45
Figure 26: Aspergillosis Market, Global, Prominent Sponsors, 2010 46
Figure 27: Aspergillosis Market, Global, Overall Sponsors, 2010 46
Figure 28: Aspergillosis, Market, Global, Companies by Phase, 2010 48
Figure 29: Aspergillosis Market, Drivers and Barriers, 2010 49
Figure 30:  Implications for Future Market Competition in the Aspergillosis Therapeutics Market, 2011 50
Figure 31: Aspergillosis Therapeutics Market - Clinical Pipeline by Company, 2010 51
Figure 32: GlobalData Market Forecasting Model 61